CBS 2019
CBSMD教育中心
中 文

推荐文献

Abstract

Recommended Article

Coronary Catheterization and Percutaneous Coronary Intervention in China: 10-Year Results From the China PEACE-Retrospective CathPCI Study The HACD4 haplotype as a risk factor for atherosclerosis in males CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD SCAI Expert Consensus Statement Update on Best Practices for Transradial Angiography and Intervention Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents LOX-1 in Atherosclerosis and Myocardial Ischemia: Biology, Genetics, and Modulation

Original ResearchVolume 114, August 2021, Pages 11-24

JOURNAL:Trends Food Sci Technol. Article Link

Potential protective mechanisms of green tea polyphenol EGCG against COVID-19

Y Zhang, B Wernly, ZCh Zhou et al. Keywords: COVID-19; prevention; green tea; EGCG

ABSTRACT

BACKGROUND - The world is in the midst of the COVID-19 pandemic. In this comprehensive review, we discuss the potential protective effects of ()-epigallocatechin-3-gallate (EGCG), a major constituent of green tea, against COVID-19.


SCOPE AND APPROACH - Information from literature of clinical symptoms and molecular pathology of COVID-19 as well as relevant publications in which EGCG shows potential protective activities against COVID-19 is integrated and evaluated.


KEY FINDINGS AND CONCLUSIONS - EGCG, via activating Nrf2, can suppress ACE2 (a cellular receptor for SARS-CoV-2) and TMPRSS2, which mediate cell entry of the virus. Through inhibition of SARS-CoV-2 main protease, EGCG may inhibit viral reproduction. EGCG via its broad antioxidant activity may protect against SARS-CoV-2 evoked mitochondrial ROS (which promote SARS-CoV-2 replication) and against ROS burst inflicted by neutrophil extracellular traps. By suppressing ER-resident GRP78 activity and expression, EGCG can potentially inhibit SARS-CoV-2 life cycle. EGCG also shows protective effects against 1) cytokine storm-associated acute lung injury/acute respiratory distress syndrome, 2) thrombosis via suppressing tissue factors and activating platelets, 3) sepsis by inactivating redox-sensitive HMGB1, and 4) lung fibrosis through augmenting Nrf2 and suppressing NF-κB. These activities remain to be further substantiated in animals and humans. The possible concerted actions of EGCG suggest the importance of further studies on the prevention and treatment of COVID-19 in humans. These results also call for epidemiological studies on potential preventive effects of green tea drinking on COVID-19.